Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO).
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Dirk Schadendorf, Reinhard Dummer, Axel Hauschild, Mario Santinami, Victoria Atkinson, Mario Mandalà, Vanna Chiarion-Sileni, James M.G. Larkin, Marta Nyakas, Caroline Dutriaux, Andrew Mark Haydon, Laurent Mortier, Caroline Robert, Jacob Schachter, Christine-Elke Ortmann, Egbert De Jong, Eduard Gasal, Richard Kefford, John M. Kirkwood, Georgina V. Long
Institutions: Essen University Hospital, University Hospital Zurich, University Hospital Schleswig-Holstein, Fondazione IRCCS Istituto Nazionale dei Tumori, The University of Queensland, Princess Alexandra Hospital, Gallipoli Medical Research Foundation, Ospedale Papa Giovanni XXIII, Istituto Oncologico Veneto, Royal Marsden NHS Foundation Trust, Oslo University Hospital, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, The Alfred Hospital, Inserm, Université de Lille, Institut Gustave Roussy, Sheba Medical Center, Novartis (Switzerland), The University of Sydney, Westmead Hospital, Melanoma Institute Australia, Macquarie University, University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2947544001